Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Somatostatinoma × lutetium Lu 177 dotatate × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neuroendocrine Tumors 33 Paraganglioma 6 Meningioma 6 Pheochromocytoma 5 Gastro-enteropancreatic neuroendocrine tumor 5 Carcinoma, Neuroendocrine 4 Carcinoid Tumor 3 Adenoma, Islet Cell 3 Neuroblastoma 2 Medulloblastoma 2 Carcinoma, Merkel Cell 2 Carcinoma, Medullary 2 Somatostatinoma 1 Serotonin Syndrome 1 Prostatic Neoplasms 1 Pituitary Neoplasms 1 Parathyroid Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms, Germ Cell and Embryonal 1 Neoplasms 1 Metastatic Digestive System Neuroendocrine Tumor G1 1 Hypertension 1 Glioma 1 Glioblastoma 1 Extensive Stage Small Cell Lung Cancer 1 Ependymoma 1 Disease Progression 1 Digestive System Neuroendocrine Tumor G1 1 Diffuse Intrinsic Pontine Glioma 1 Central Nervous System Neoplasms 1

Interventions

Capecitabine 6 Temozolomide 5 Octreotide 4 Leucovorin 4 Fluorouracil 3 Everolimus 3 Bevacizumab 3 vatalanib 2 pentetreotide 2 Trastuzumab 2 Sunitinib 2 Oxaliplatin 2 Magnetic Resonance Spectroscopy 2 Cisplatin 2 Bortezomib 2 veliparib 1 tipifarnib 1 temsirolimus 1 sapanisertib 1 romidepsin 1 regorafenib 1 pazopanib 1 palbociclib 1 motesanib diphosphate 1 lutetium Lu 177 dotatate 1 irinotecan sucrosofate 1 gallium Ga 68 dotatate 1 dehydroftorafur 1 cixutumumab 1 batifiban 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02230176 2025-04-20

OCCLURANDOM

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Somatostatinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡